A Phase 2 interventional study of AVP-786 and Placebo in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 17 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd. — 3 open to participants now, 4 under way, 3 of them phase 3. Schizophrenia · Otsuka Holdings Co., Ltd..
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 53rd largest by enrollment of the 111 interventional ones that give a count, is one of 3 that started in 2015, is one of 9 in phase 2, and was the 71st registered.
3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.
Browse Schizophrenia studies →3 of the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18+
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18–74
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in United States
Ages 18–55 · Men only · Healthy volunteers
By country, each count listing its studies:
Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 14 · Phase 3 54 · Phase 4 13
First in 1998; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 145 is above the median of 70 across 2,953 interventional studies indexed under Schizophrenia.
Median enrollment 125 across the 111 interventional studies, 281 across the 8 observational. Of the 111 that completed or were terminated, 64 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
2 of the studies in Schizophrenia by Otsuka Holdings Co., Ltd. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05325645Phase 3Otsuka Pharmaceutical Co., Ltd.Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia | 2027-09 |
| NCT07455084Otsuka Pharmaceutical Development & Commercialization, Inc.A Study to Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in Healthy Male Adults | 2026-12-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objectives of this 12-week study are to evaluate the efficacy, safety, and tolerability of AVP-786 as an adjunctive treatment compared with placebo in patients with residual schizophrenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo capsules administered twice a day over a 12-week period
Drug: Placebo
AVP-786 dose 2 capsules administered twice a day over a 12-week period
Drug: AVP-786
Drug pages: Deudextromethorphan · Quinidine
Change From Baseline in the 16-Item Negative Symptom Assessment (NSA-16) Total Score at Week 6 and Week 12
The NSA-16 is a measure of the presence, severity, and range of negative symptoms associated with schizophrenia. It has a high interrater and test-retest reliability across languages and cultures. The NSA-16 uses a 5-factor model to describe negative symptoms: (1) communication, (2) emotion/affect, (3) social involvement, (4) motivation, and (5) retardation. The possible NSA-16 total score ranges from 16 to 96, with a higher score indicating a worse condition. Change was Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 and Week 12
The PANSS is a 30-item clinical scale that is extensively used as a reliable and valid measure for negative symptom trials. The PANNS consists of 6 subscales: positive subscale; negative subscale; general psychopathology subscale; prosocial factors (active social avoidance, emotional withdrawal, passive/apathetic social withdrawal, stereotyped thinking, hallucinatory behavior, suspiciousness/persecution); Marder negative factors (blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of spontaneity and flow of conversation, motor retardation, active social avoidance); excitement component (excitement, hostility, tension, uncooperativeness, poor impulse control). Each item was scored from "1" (absent) to "7" (extremely severe). The PANSS total score ranges from 30 to 210, with a higher score indicating greater severity of symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Change From Baseline in the PANSS Negative Subscale Score at Week 6 and Week 12
The negative subscale includes items N1 - N7 in the PANSS. Each item was scored from "1" (absent) to "7" (extremely severe). The score ranges from 7 to 49, with higher scores indicative of greater severity of the negative symptoms. Change from Baseline was calculated as the post-Baseline score minus the Baseline score.
Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Change From Baseline in the PANSS Marder Negative Factor Score at Week 6 and Week 12
The Marder negative factors comprise 7 items of the PANSS: N1 (blunted affect); N2 (emotional withdrawal); N3 (poor rapport); N4 (passive/apathetic social withdrawal); N6 (lack of spontaneity and flow of conversation); G7 (motor retardation), and G16 (active social avoidance). Each item is scored from "1" (absent) to "7" (extremely severe). The score ranges from 7 to 49, with higher scores indicative of greater severity of the negative symptoms of schizophrenia. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Change From Baseline in the PANSS Prosocial Factor Subscale Score at Week 6 at Week 12
The prosocial factors include items: G16 (active social avoidance); N2 (emotional withdrawal); N4 (passive/apathetic social withdrawal); N7 (stereotyped thinking); P3 (hallucinatory behavior); and P6 (suspiciousness/persecution) in the PANSS. Each item was scored from "1" (absent) to "7" (extremely severe). The score ranges from 6 to 42, with higher scores indicative of greater severity of the specific negative symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Change From Baseline in the PANSS Positive Subscale Score at Week 6 and Week 12
The positive subscale includes items P1 - P7 in the PANSS. Each item is scored from "1" (absent) to "7" (extremely severe). The score ranges from 7 to 49, with higher scores indicative of greater severity of the positive symptoms of schizophrenia. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Change From Baseline in the PANSS General Psychopathology Subscale Score at Week 6 and Week 12
The general psychopathology subscale includes items G1 - G16 in the PANSS. Each item was scored from "1" (absent) to "7" (extremely severe). The score ranges from 16 to 112, with higher scores indicative of greater severity of symptoms of schizophrenia. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Change From Baseline in the PANSS Excitement Component Subscale Score at Week 6 and Week 12
The excitement component includes items: P4 (excitement); P7 (hostility); G4 (tension); G8 (uncooperativeness); and G14 (poor impulse control). Each item is scored from "1" (absent) to "7" (extremely severe). The score ranges from 5 to 35, with higher scores indicative of greater severity of symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Change From Baseline in the NSA-16 Communication Domain Score at Week 6 and Week 12
NSA-16 Communication Factor Domain scores range from 4 to 24, with higher scores indicating greater clinical severity of symptoms. Negative values indicate improvement. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Change From Baseline in the NSA-16 Emotion/Affect Domain Score at Week 6 and Week 12
NSA-16 Emotion/Affect Domain scores range from 3 to 18, with higher scores indicating a greater clinical severity of symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Change From Baseline in the NSA-16 Social Involvement Domain Score at Week 6 and Week 12
NSA-16 Social Involvement Factor Domain scores range from 3 to 18, with higher scores indicating greater clinical severity of symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Change From Baseline in the NSA-16 Motivation Domain Score at Week 6 and Week 12
NSA-16 Motivation Factor Domain scores range from 4 to 24, with higher scores indicating greater clinical severity of symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Change From Baseline in the NSA-16 Retardation Domain Score at Week 6 at Week 12
NSA-16 Retardation Factor Domain scores range from 3 to 18, with higher scores indicating greater clinical severity of symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Change From Baseline in the NSA-16 Global Negative Symptoms Score at Week 6 and Week 12
The global negative symptoms rating in the NSA-16 is a single score based on the overall impression of severity of negative symptoms on a 1 to 7 scale, where higher scores indicate greater severity. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Change From Baseline in the NSA-16 Global Level of Functioning Score at Week 6 and Week 12
The global level of functioning is a single score on a scale of 1 to 7 that provides the overall assessment of the participant's level of functioning, with higher scores indicative of severe impairment in functioning. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Change From Baseline in the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) Composite Score at Week 6 and Week 12
The MCCB is the standard tool for assessing cognitive change in trials of cognitive-enhancing agents in schizophrenia and is used to provide a relatively brief evaluation of key cognitive domains relevant to schizophrenia and related disorders. It is made up of 10 tests that measure 7 cognitive domains: Speed of Processing; Attention/Vigilance; Working Memory; Verbal Learning; Visual Learning; Reasoning and Problem Solving; and Social Cognition. The MCCB was to be conducted at approximately the same time of day (+/- 2 hours) and preferably in the morning. The MCCB composite score ranges from 0 to 70, with higher scores indicative of less severe cognition symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Mean Actual Clinical Global Impression of Severity (CGI-S) of Illness Score at Week 6 and Week 12
The CGI is an assessment of a participant's global functioning prior to and after initiating study medication and provides an overall clinician-determined summary measure that takes into account knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. It is based on a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with participants who have the same diagnosis. Considering the total clinical experience, a participant is assessed on severity of mental illness at the time of rating: 1 (normal, not at all ill); 2 (borderline mentally ill); 3 (mildly ill); 4 (moderately ill); 5 (markedly ill); 6 (severely ill); or 7 (among the most extremely ill participants). Scores range from 1 to 7, with higher scores indicative of greater severity of illness.
Time frame: Week 6 (Stage 1); Week 12 (Stage 2)
Mean Actual Clinical Global Impression of Change (CGI-C) Score at Week 6 and Week 12
The CGI is an assessment of the participant's global functioning prior to and after initiating a study medication and provides an overall clinician-determined summary measure that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. It is based on a 7-point scale that requires the clinician to rate the change of the participant's condition at the time of assessment, relative to the clinician's past experience with the participant's condition at admission. Considering the total clinical experienced, a participant is assessed for change of mental illness as: 1 (very much improved); 2 (much improved); 3 (minimally improved); 4 (no change); 5 (minimally worse); 6 (much worse); or 7 (very much worse). Scores range from 1 to 7, with higher scores indicative of greater severity of illness.
Time frame: Baseline, Week 6 (Stage 1), Week 12 (Stage 2)
Mean Actual Patient Global Impression of Change (PGI-C) Score at Week 6 at Week 12
The PGI-C is a 7-point, participant-rated scale used to assess treatment response as: 0=Not assessed; 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally 6=worse; or 7=very much worse. Week 6 and Week 12 scores are relative to Stage 1 Baseline.
Time frame: Baseline, Week 6 (Stage 1), Week 12 (Stage 2)
Change From Baseline in the Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Week 6 and Week 12
The CDSS is a 9-item scale derived from the Hamilton Depression Scale (Ham-D) that is designed to assess depression specifically in participants with schizophrenia. Unlike the Ham-D, the CDSS does not contain depressive symptoms that overlap with negative symptoms of schizophrenia, such as anhedonia and social withdrawal. Each item on the scale is scored as: 0 (absent); 1 (mild); 2 (moderate); or 3 (severe). The CDSS is obtained by adding each of the item scores. A score above 6 has an 82% specificity and 85% sensitivity for predicting the presence of a major depressive episode. The CDSS score ranges from 0 to 27, with higher scores indicative of severe symptoms of depression. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Change From Baseline in the Effort Expenditure for Reward Task (EEfRT) Score for Baseline Press Rate at Week 6 and Week 12
The EEfRT is a multi-trial computerized task in which participants are given the opportunity on each trial to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. The test measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. The ratio of hard task choices with moderate probability reward is used as an outcome measure for negative symptoms. EEfRT scores are analyzed for 8 variables. Variable 1 is the Baseline press rate and is defined as the value coded as average presses/second. Scores range from 0 to 9, with higher scores indicative of faster button pressing ability. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Change From Baseline in the EEfRT Score for Choice Reaction Time (RT) 1st 50 at Week 6 and Week 12
The EEfRT is a multi-trial computerized test that reliably measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. For each trial, participants are asked to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. EEfRT scores are analyzed for 8 variables. Variable 2 is the choice RT and is defined as the average RT measured in milliseconds for making a choice during the first 50 trials. Scores range from 0 to 10,000. The target range is greater than 500. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Change From Baseline in the EEfRT Score for Completed Tasks at Week 6 and Week 12
The EEfRT is a multi-trial computerized test that reliably measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. For each trial, participants are asked to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. EEfRT scores are analyzed for 8 variables. Variable 3 is the proportion of completed task (easy or hard) during the first 50 trials. Scores range from 0 to 1, with higher scores indicative of better task compliance. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Change From Baseline in the EEfRT Score for 12% Probability-Proportion High Effort Opts at Week 6 and Week 12
The EEfRT is a multi-trial computerized test that reliably measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. For each trial, participants are asked to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. EEfRT scores are analyzed for 8 variables. Variable 4 is the proportion of hard task choices made for the low (12%) probability condition during the first 50 trials of the task. Scores range from 0 to 1, with higher scores indicative of greater effort expenditure. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Change From Baseline in the EEfRT Score for 50% Probability-Proportion High Effort Opts 1st 50 at Week 6 and Week 12
The EEfRT is a multi-trial computerized test that reliably measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. For each trial, participants are asked to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. EEfRT scores are analyzed for 8 variables. Variable 5 is the proportion of hard task choices made for the medium (50%) probability condition during the first 50 trials of the task. Scores range from 0 to 1, with higher scores indicative of greater effort expenditure. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Change From Baseline in the EEfRT Score for 88% Probability-Proportion High Effort Opts 1st 50 at Week 6 and Week 12
The EEfRT is a multi-trial computerized test that reliably measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. For each trial, participants are asked to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. EEfRT scores are analyzed for 8 variables. Variable 6 is the proportion of hard task choices made for the hard (88%) probability condition during the first 50 trials of the task. Scores range from 0 to 1, with higher scores indicative of greater effort expenditure. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Change From Baseline in the EEfRT Score for All-Proportion High Effort Opts 1st 50 at Week 6 and Week 12
The EEfRT is a multi-trial computerized test that reliably measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. For each trial, participants are asked to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. EEfRT scores are analyzed for 8 variables. Variable 7 is the overall proportion of hard task choices made for the first 50 trials of the task. Scores range from 0 to 1, with higher scores indicative of greater effort expenditure. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Change From Baseline in the EEfRT Score for Difference - Proportion High Effort Opts 1st 50 at Week 6 and Week 12
The EEfRT is a multi-trial computerized test that reliably measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. For each trial, participants are asked to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. EEfRT scores are analyzed for 8 variables. Variable 8 is the difference between the proportion of hard task choices made for the high probability condition during the first 50 trials of the task. Scores range from -1 to 1, with higher scores indicative of greater sensitivity to probability information. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Number of Participants With a Reduction of 20% or Greater in the PANSS Total Score at Week 6 and Week 12
Treatment effect was evaluated by analyzing the proportion of participants with a 20% reduction from Baseline in the PANSS total score with SPCD analysis.
Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Change From Baseline in the 4-Item NSA (NSA-4) Total Score at Week 6 and Week 12
The NSA-4 is comprised of the 4 NSA-16 items as follows: 1) restricted speech quantity, 2) emotion: reduced range, 3) reduced social drive, and 4) reduced interests, as well as an overall global rating of negative symptoms. The NSA-16 is a measure of the presence, severity, and range of negative symptoms associated with schizophrenia. It has a high interrater and test-retest reliability across languages and cultures. The possible NSA-4 total score ranges from 4 to 24, with higher scores indicating greater clinical severity of symptoms. Change was Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2)
Of the 145 participants randomized at the beginning of the study, 127 patients met the criteria for the Modified Intent-to-Treat (mITT) Population and were included in the Stage 1 mITT Population. A total of 108 participants were included in the Stage 2 mITT Population.
| Milestone | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Started | 47 | 80 | 0 | 0 | 0 | 0 | 0 |
| Completed | 43 | 67 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 4 | 13 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 7 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 30 | 33 | 2 | 1 | 42 |
| Completed | 0 | 0 | 28 | 32 | 2 | 1 | 42 |
| Not completed | 0 | 0 | 2 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Antipsychotic medication changed | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
The NSA-16 is a measure of the presence, severity, and range of negative symptoms associated with schizophrenia. It has a high interrater and test-retest reliability across languages and cultures. The NSA-16 uses a 5-factor model to describe negative symptoms: (1) communication, (2) emotion/affect, (3) social involvement, (4) motivation, and (5) retardation. The possible NSA-16 total score ranges from 16 to 96, with a higher score indicating a worse condition. Change was Baseline was calculated as the post-Baseline value minus the Baseline value.
| score on a scale | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Stage 1 Baseline | 61.0 ± 7.53 | 60.4 ± 7.71 | — | — | — | — | — |
| Change from Baseline at Week 6 | -5.0 ± 5.64 | -3.4 ± 5.54 | — | — | — | — | — |
| Stage 2 Baseline | — | — | 57.6 ± 9.39 | 57.6 ± 9.09 | — | — | — |
| Change from Baseline at Week 12 | — | — | -2.4 ± 5.88 | -3.7 ± 6.41 | — | — | — |
The PANSS is a 30-item clinical scale that is extensively used as a reliable and valid measure for negative symptom trials. The PANNS consists of 6 subscales: positive subscale; negative subscale; general psychopathology subscale; prosocial factors (active social avoidance, emotional withdrawal, passive/apathetic social withdrawal, stereotyped thinking, hallucinatory behavior, suspiciousness/persecution); Marder negative factors (blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of spontaneity and flow of conversation, motor retardation, active social avoidance); excitement component (excitement, hostility, tension, uncooperativeness, poor impulse control). Each item was scored from "1" (absent) to "7" (extremely severe). The PANSS total score ranges from 30 to 210, with a higher score indicating greater severity of symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| score on a scale | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Stage 1 Baseline | 67.4 ± 8.26 | 68.7 ± 7.99 | — | — | — | — | — |
| Change from Baseline at Week 6 | -4.7 ± 6.98 | -2.5 ± 6.50 | — | — | — | — | — |
| Stage 2 Baseline | — | — | 67.1 ± 9.00 | 65.6 ± 8.07 | — | — | — |
| Change from Baseline at Week 12 | — | — | -1.4 ± 7.64 | -4.0 ± 7.71 | — | — | — |
The negative subscale includes items N1 - N7 in the PANSS. Each item was scored from "1" (absent) to "7" (extremely severe). The score ranges from 7 to 49, with higher scores indicative of greater severity of the negative symptoms. Change from Baseline was calculated as the post-Baseline score minus the Baseline score.
| score on a scale | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Stage 1 Baseline | 24.6 ± 3.51 | 25.2 ± 3.64 | — | — | — | — | — |
| Change from Baseline at Week 6 | -2.2 ± 3.33 | -1.5 ± 3.81 | — | — | — | — | — |
| Stage 2 Baseline | — | — | 24.4 ± 4.55 | 23.6 ± 4.53 | — | — | — |
| Change from Baseline at Week 12 | — | — | -1.0 ± 2.69 | -2.3 ± 3.12 | — | — | — |
The Marder negative factors comprise 7 items of the PANSS: N1 (blunted affect); N2 (emotional withdrawal); N3 (poor rapport); N4 (passive/apathetic social withdrawal); N6 (lack of spontaneity and flow of conversation); G7 (motor retardation), and G16 (active social avoidance). Each item is scored from "1" (absent) to "7" (extremely severe). The score ranges from 7 to 49, with higher scores indicative of greater severity of the negative symptoms of schizophrenia. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| score on a scale | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Stage 1 Baseline | 24.1 ± 4.24 | 24.2 ± 3.81 | — | — | — | — | — |
| Change from Baseline at Week 6 | -2.1 ± 3.34 | -1.6 ± 3.48 | — | — | — | — | — |
| Stage 2 Baseline | — | — | 23.0 ± 4.62 | 22.3 ± 5.45 | — | — | — |
| Change from Baseline at Week 12 | — | — | -0.8 ± 2.80 | -2.5 ± 4.27 | — | — | — |
The prosocial factors include items: G16 (active social avoidance); N2 (emotional withdrawal); N4 (passive/apathetic social withdrawal); N7 (stereotyped thinking); P3 (hallucinatory behavior); and P6 (suspiciousness/persecution) in the PANSS. Each item was scored from "1" (absent) to "7" (extremely severe). The score ranges from 6 to 42, with higher scores indicative of greater severity of the specific negative symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| score on a scale | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Stage 1 Baseline | 18.3 ± 3.24 | 18.4 ± 2.92 | — | — | — | — | — |
| Change from Baseline at Week 6 | -2.0 ± 2.18 | -1.1 ± 2.53 | — | — | — | — | — |
| Stage 2 Baseline | — | — | 17.7 ± 3.27 | 17.0 ± 3.30 | — | — | — |
| Change from Baseline at Week 12 | — | — | -0.7 ± 2.02 | -1.4 ± 2.35 | — | — | — |
The positive subscale includes items P1 - P7 in the PANSS. Each item is scored from "1" (absent) to "7" (extremely severe). The score ranges from 7 to 49, with higher scores indicative of greater severity of the positive symptoms of schizophrenia. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| score on a scale | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Stage 1 Baseline | 13.6 ± 3.65 | 13.4 ± 2.81 | — | — | — | — | — |
| Change from Baseline at Week 6 | -0.8 ± 2.63 | -0.3 ± 2.57 | — | — | — | — | — |
| Stage 2 Baseline | — | — | 13.1 ± 3.64 | 13.3 ± 3.39 | — | — | — |
| Change from Baseline at Week 12 | — | — | -0.4 ± 1.99 | -0.3 ± 2.47 | — | — | — |
The general psychopathology subscale includes items G1 - G16 in the PANSS. Each item was scored from "1" (absent) to "7" (extremely severe). The score ranges from 16 to 112, with higher scores indicative of greater severity of symptoms of schizophrenia. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| score on a scale | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Stage 1 Baseline | 29.1 ± 4.66 | 30.1 ± 5.05 | — | — | — | — | — |
| Change from Baseline at Week 6 | -1.7 ± 4.04 | -0.7 ± 3.21 | — | — | — | — | — |
| Stage 2 Baseline | — | — | 29.7 ± 5.40 | 28.7 ± 4.84 | — | — | — |
| Change from Baseline at Week 12 | — | — | 0.0 ± 5.14 | -1.3 ± 5.10 | — | — | — |
The excitement component includes items: P4 (excitement); P7 (hostility); G4 (tension); G8 (uncooperativeness); and G14 (poor impulse control). Each item is scored from "1" (absent) to "7" (extremely severe). The score ranges from 5 to 35, with higher scores indicative of greater severity of symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| score on a scale | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Stage 1 Baseline | 6.2 ± 1.57 | 6.3 ± 2.10 | — | — | — | — | — |
| Change from Baseline at Week 6 | -0.4 ± 1.64 | -0.2 ± 1.57 | — | — | — | — | — |
| Stage 2 Baseline | — | — | 5.8 ± 1.27 | 6.7 ± 2.59 | — | — | — |
| Change from Baseline at Week 12 | — | — | 0.0 ± 2.04 | -0.1 ± 1.77 | — | — | — |
NSA-16 Communication Factor Domain scores range from 4 to 24, with higher scores indicating greater clinical severity of symptoms. Negative values indicate improvement. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| score on a scale | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Stage 1 Baseline | 12.5 ± 2.54 | 12.6 ± 2.71 | — | — | — | — | — |
| Change from Baseline at Week 6 | -1.3 ± 2.32 | -1.0 ± 1.91 | — | — | — | — | — |
| Stage 2 Baseline | — | — | 12.0 ± 2.98 | 11.8 ± 3.12 | — | — | — |
| Change from Baseline at Week 12 | — | — | -0.4 ± 1.86 | -1.0 ± 1.56 | — | — | — |
NSA-16 Emotion/Affect Domain scores range from 3 to 18, with higher scores indicating a greater clinical severity of symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| score on a scale | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Stage 1 Baseline | 12.6 ± 2.11 | 12.2 ± 1.81 | — | — | — | — | — |
| Change from Baseline at Week 6 | -1.0 ± 1.28 | -0.6 ± 1.54 | — | — | — | — | — |
| Stage 2 Baseline | — | — | 11.7 ± 1.84 | 11.7 ± 2.09 | — | — | — |
| Change from Baseline at Week 12 | — | — | -0.4 ± 1.50 | -0.6 ± 1.36 | — | — | — |
NSA-16 Social Involvement Factor Domain scores range from 3 to 18, with higher scores indicating greater clinical severity of symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| score on a scale | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Stage 1 Baseline | 12.2 ± 2.02 | 12.2 ± 2.20 | — | — | — | — | — |
| Change from Baseline at Week 6 | -0.6 ± 1.87 | -0.3 ± 1.92 | — | — | — | — | — |
| Stage 2 Baseline | — | — | 12.1 ± 2.12 | 12.0 ± 2.56 | — | — | — |
| Change from Baseline at Week 12 | — | — | -0.8 ± 1.40 | -1.1 ± 2.51 | — | — | — |
NSA-16 Motivation Factor Domain scores range from 4 to 24, with higher scores indicating greater clinical severity of symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| score on a scale | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Stage 1 Baseline | 16.5 ± 2.37 | 16.7 ± 2.33 | — | — | — | — | — |
| Change from Baseline at Week 6 | -1.4 ± 1.96 | -0.9 ± 1.80 | — | — | — | — | — |
| Stage 2 Baseline | — | — | 15.8 ± 2.61 | 15.8 ± 2.39 | — | — | — |
| Change from Baseline at Week 12 | — | — | -0.4 ± 2.13 | -0.4 ± 2.09 | — | — | — |
NSA-16 Retardation Factor Domain scores range from 3 to 18, with higher scores indicating greater clinical severity of symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| score on a scale | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Stage 1 Baseline | 7.2 ± 1.54 | 6.7 ± 1.61 | — | — | — | — | — |
| Change from Baseline at Week 6 | -0.8 ± 1.46 | -0.6 ± 1.20 | — | — | — | — | — |
| Stage 2 Baseline | — | — | 6.0 ± 2.00 | 6.3 ± 2.05 | — | — | — |
| Change from Baseline at Week 12 | — | — | -0.3 ± 1.20 | -0.5 ± 1.81 | — | — | — |
The global negative symptoms rating in the NSA-16 is a single score based on the overall impression of severity of negative symptoms on a 1 to 7 scale, where higher scores indicate greater severity. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| score on a scale | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Stage 1 Baseline | 4.6 ± 0.64 | 4.6 ± 0.61 | — | — | — | — | — |
| Change from Baseline at Week 6 | -0.4 ± 0.68 | -0.2 ± 0.64 | — | — | — | — | — |
| Stage 2 Baseline | — | — | 4.3 ± 0.71 | 4.4 ± 0.75 | — | — | — |
| Change from Baseline at Week 12 | — | — | -0.1 ± 0.51 | -0.5 ± 0.75 | — | — | — |
The global level of functioning is a single score on a scale of 1 to 7 that provides the overall assessment of the participant's level of functioning, with higher scores indicative of severe impairment in functioning. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| score on a scale | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Stage 1 Baseline | 4.7 ± 0.73 | 4.6 ± 0.63 | — | — | — | — | — |
| Change from Baseline at Week 6 | -0.4 ± 0.61 | -0.2 ± 0.55 | — | — | — | — | — |
| Stage 2 Baseline | — | — | 4.5 ± 0.74 | 4.4 ± 0.70 | — | — | — |
| Change from Baseline at Week 12 | — | — | -0.3 ± 0.52 | -0.3 ± 0.64 | — | — | — |
The MCCB is the standard tool for assessing cognitive change in trials of cognitive-enhancing agents in schizophrenia and is used to provide a relatively brief evaluation of key cognitive domains relevant to schizophrenia and related disorders. It is made up of 10 tests that measure 7 cognitive domains: Speed of Processing; Attention/Vigilance; Working Memory; Verbal Learning; Visual Learning; Reasoning and Problem Solving; and Social Cognition. The MCCB was to be conducted at approximately the same time of day (+/- 2 hours) and preferably in the morning. The MCCB composite score ranges from 0 to 70, with higher scores indicative of less severe cognition symptoms. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| score on a scale | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Stage 1 Baseline | 32.5 ± 11.37 | 28.8 ± 13.09 | — | — | — | — | — |
| Change from Baseline at Week 6 | 1.2 ± 5.11 | 1.6 ± 4.55 | — | — | — | — | — |
| Stage 2 Baseline | — | — | 31.7 ± 14.99 | 28.9 ± 10.69 | — | — | — |
| Change from Baseline at Week 12 | — | — | -1.6 ± 4.06 | 1.6 ± 3.71 | — | — | — |
The CGI is an assessment of a participant's global functioning prior to and after initiating study medication and provides an overall clinician-determined summary measure that takes into account knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. It is based on a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with participants who have the same diagnosis. Considering the total clinical experience, a participant is assessed on severity of mental illness at the time of rating: 1 (normal, not at all ill); 2 (borderline mentally ill); 3 (mildly ill); 4 (moderately ill); 5 (markedly ill); 6 (severely ill); or 7 (among the most extremely ill participants). Scores range from 1 to 7, with higher scores indicative of greater severity of illness.
| score on a scale | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Week 6 | 3.6 ± 0.80 | 3.8 ± 0.77 | — | — | — | — | — |
| Week 12 | — | — | 3.7 ± 0.75 | 3.5 ± 0.93 | — | — | — |
The CGI is an assessment of the participant's global functioning prior to and after initiating a study medication and provides an overall clinician-determined summary measure that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. It is based on a 7-point scale that requires the clinician to rate the change of the participant's condition at the time of assessment, relative to the clinician's past experience with the participant's condition at admission. Considering the total clinical experienced, a participant is assessed for change of mental illness as: 1 (very much improved); 2 (much improved); 3 (minimally improved); 4 (no change); 5 (minimally worse); 6 (much worse); or 7 (very much worse). Scores range from 1 to 7, with higher scores indicative of greater severity of illness.
| score on a scale | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Week 6 | 3.4 ± 0.80 | 3.6 ± 0.69 | — | — | — | — | — |
| Week 12 | — | — | 3.8 ± 0.90 | 3.5 ± 0.80 | — | — | — |
The PGI-C is a 7-point, participant-rated scale used to assess treatment response as: 0=Not assessed; 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally 6=worse; or 7=very much worse. Week 6 and Week 12 scores are relative to Stage 1 Baseline.
| score on a scale | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Week 6 | 3.1 ± 0.94 | 3.2 ± 1.01 | — | — | — | — | — |
| Week 12 | — | — | 3.3 ± 0.78 | 2.9 ± 1.11 | — | — | — |
The CDSS is a 9-item scale derived from the Hamilton Depression Scale (Ham-D) that is designed to assess depression specifically in participants with schizophrenia. Unlike the Ham-D, the CDSS does not contain depressive symptoms that overlap with negative symptoms of schizophrenia, such as anhedonia and social withdrawal. Each item on the scale is scored as: 0 (absent); 1 (mild); 2 (moderate); or 3 (severe). The CDSS is obtained by adding each of the item scores. A score above 6 has an 82% specificity and 85% sensitivity for predicting the presence of a major depressive episode. The CDSS score ranges from 0 to 27, with higher scores indicative of severe symptoms of depression. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| score on a scale | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Stage 1 Baseline | 1.1 ± 1.34 | 0.9 ± 1.31 | — | — | — | — | — |
| Chane from Baseline at Week 6 | -0.2 ± 1.34 | -0.1 ± 1.02 | — | — | — | — | — |
| Stage 2 Baseline | — | — | 1.0 ± 1.56 | 0.8 ± 1.54 | — | — | — |
| Change from Baseline at Week 12 | — | — | -0.4 ± 1.24 | -0.0 ± 1.66 | — | — | — |
The EEfRT is a multi-trial computerized task in which participants are given the opportunity on each trial to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. The test measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. The ratio of hard task choices with moderate probability reward is used as an outcome measure for negative symptoms. EEfRT scores are analyzed for 8 variables. Variable 1 is the Baseline press rate and is defined as the value coded as average presses/second. Scores range from 0 to 9, with higher scores indicative of faster button pressing ability. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| score on a scale | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Stage 1 Baseline | 3.39 ± 1.137 | 3.39 ± 1.112 | — | — | — | — | — |
| Change from Baseline at Week 6 | 0.461 ± 0.844 | 0.195 ± 1.181 | — | — | — | — | — |
| Stage 2 Baseline | — | — | 3.38 ± 1.284 | 3.67 ± 0.904 | — | — | — |
| Change from Baseline at Week 12 | — | — | -0.109 ± 0.909 | 0.354 ± 1.076 | — | — | — |
The EEfRT is a multi-trial computerized test that reliably measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. For each trial, participants are asked to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. EEfRT scores are analyzed for 8 variables. Variable 2 is the choice RT and is defined as the average RT measured in milliseconds for making a choice during the first 50 trials. Scores range from 0 to 10,000. The target range is greater than 500. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| score on a scale | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Stage 1 Baseline | 1339.5 ± 838.40 | 1659.4 ± 1063.02 | — | — | — | — | — |
| Change from Baseline at Week 6 | -255.1 ± 551.65 | -346.6 ± 1108.63 | — | — | — | — | — |
| Stage 2 Baseline | — | — | 1309.4 ± 595.02 | 1283.5 ± 875.79 | — | — | — |
| Change from Baseline at Week 12 | — | — | -288.8 ± 527.42 | -110.2 ± 812.66 | — | — | — |
The EEfRT is a multi-trial computerized test that reliably measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. For each trial, participants are asked to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. EEfRT scores are analyzed for 8 variables. Variable 3 is the proportion of completed task (easy or hard) during the first 50 trials. Scores range from 0 to 1, with higher scores indicative of better task compliance. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| score on a scale | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Stage 1 Baseline | 0.790 ± 0.285 | 0.749 ± 0.294 | — | — | — | — | — |
| Change from Baseline at Week 6 | -0.032 ± 0.196 | 0.001 ± 0.209 | — | — | — | — | — |
| Stage 2 Baseline | — | — | 0.703 ± 0.329 | 0.779 ± 0.254 | — | — | — |
| Change from Baseline at Week 12 | — | — | 0.049 ± 0.223 | -0.022 ± 0.173 | — | — | — |
The EEfRT is a multi-trial computerized test that reliably measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. For each trial, participants are asked to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. EEfRT scores are analyzed for 8 variables. Variable 4 is the proportion of hard task choices made for the low (12%) probability condition during the first 50 trials of the task. Scores range from 0 to 1, with higher scores indicative of greater effort expenditure. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| score on a scale | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Stage 1 Baseline | 0.080 ± 0.071 | 0.0755 ± 0.079 | — | — | — | — | — |
| Change from Baseline at Week 6 | -0.021 ± 0.064 | -0.004 ± 0.082 | — | — | — | — | — |
| Stage 2 Baseline | — | — | 0.040 ± 0.049 | 0.071 ± 0.063 | — | — | — |
| Change from Baseline at Week 12 | — | — | 0.000 ± 0.045 | -0.027 ± 0.051 | — | — | — |
The EEfRT is a multi-trial computerized test that reliably measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. For each trial, participants are asked to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. EEfRT scores are analyzed for 8 variables. Variable 5 is the proportion of hard task choices made for the medium (50%) probability condition during the first 50 trials of the task. Scores range from 0 to 1, with higher scores indicative of greater effort expenditure. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| score on a scale | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Stage 1 Baseline | 0.088 ± 0.070 | 0.078 ± 0.081 | — | — | — | — | — |
| Change from Baseline at Week 6 | -0.026 ± 0.055 | -0.012 ± 0.102 | — | — | — | — | — |
| Stage 2 Baseline | — | — | 0.060 ± 0.057 | 0.062 ± 0.078 | — | — | — |
| Change from Baseline at Week 12 | — | — | -0.016 ± 0.068 | -0.005 ± 0.083 | — | — | — |
The EEfRT is a multi-trial computerized test that reliably measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. For each trial, participants are asked to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. EEfRT scores are analyzed for 8 variables. Variable 6 is the proportion of hard task choices made for the hard (88%) probability condition during the first 50 trials of the task. Scores range from 0 to 1, with higher scores indicative of greater effort expenditure. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| score on a scale | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Stage 1 Baseline | 0.082 ± 0.063 | 0.081 ± 0.086 | — | — | — | — | — |
| Change from Baseline at Week 6 | -0.021 ± 0.072 | -0.006 ± 0.097 | — | — | — | — | — |
| Stage 2 Baseline | — | — | 0.052 ± 0.065 | 0.078 ± 0.074 | — | — | — |
| Change from Baseline at Week 12 | — | — | -0.015 ± 0.047 | -0.015 ± 0.070 | — | — | — |
The EEfRT is a multi-trial computerized test that reliably measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. For each trial, participants are asked to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. EEfRT scores are analyzed for 8 variables. Variable 7 is the overall proportion of hard task choices made for the first 50 trials of the task. Scores range from 0 to 1, with higher scores indicative of greater effort expenditure. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| score on a scale | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Stage 1 Baseline | 0.251 ± 0.185 | 0.234 ± 0.234 | — | — | — | — | — |
| Change from Baseline at Week 6 | -0.068 ± 0.167 | -0.022 ± 0.261 | — | — | — | — | — |
| Stage 2 Baseline | — | — | 0.152 ± 0.161 | 0.210 ± 0.199 | — | — | — |
| Change from Baseline at Week 12 | — | — | -0.032 ± 0.144 | -0.047 ± 0.176 | — | — | — |
The EEfRT is a multi-trial computerized test that reliably measures drug effects on the willingness to expend effort in relation to the amount of reward or probability of reward. For each trial, participants are asked to choose between 2 tasks that differ in difficulty level and are associated with varying levels of monetary reward. EEfRT scores are analyzed for 8 variables. Variable 8 is the difference between the proportion of hard task choices made for the high probability condition during the first 50 trials of the task. Scores range from -1 to 1, with higher scores indicative of greater sensitivity to probability information. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| score on a scale | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Stage 1 Baseline | 0.002 ± 0.041 | 0.006 ± 0.037 | — | — | — | — | — |
| Change from Baseline at Week 6 | -0.001 ± 0.054 | -0.002 ± 0.050 | — | — | — | — | — |
| Stage 2 Baseline | — | — | 0.012 ± 0.032 | 0.006 ± 0.034 | — | — | — |
| Change from Baseline at Week 12 | — | — | -0.015 ± 0.037 | 0.012 ± 0.039 | — | — | — |
Treatment effect was evaluated by analyzing the proportion of participants with a 20% reduction from Baseline in the PANSS total score with SPCD analysis.
| Participants | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Week 6; Response = Yes | 5 | 3 | — | — | — | — | — |
| Week 6; Response = No | 42 | 77 | — | — | — | — | — |
| Week 12; Response = Yes | — | — | 1 | 3 | — | — | — |
| Week 12; Response = No | — | — | 29 | 30 | — | — | — |
The NSA-4 is comprised of the 4 NSA-16 items as follows: 1) restricted speech quantity, 2) emotion: reduced range, 3) reduced social drive, and 4) reduced interests, as well as an overall global rating of negative symptoms. The NSA-16 is a measure of the presence, severity, and range of negative symptoms associated with schizophrenia. It has a high interrater and test-retest reliability across languages and cultures. The possible NSA-4 total score ranges from 4 to 24, with higher scores indicating greater clinical severity of symptoms. Change was Baseline was calculated as the post-Baseline value minus the Baseline value.
| score on a scale | Stage 1: AVP-786 | Stage 1: Placebo | Stage 1 Placebo Non-responders; Stage 2: Placebo | Stage 1 Placebo Non-responders; Stage 2: AVP-786 | Stage 1 Placebo Responders; Stage 2: Placebo | Stage 1 Placebo Responders; Stage 2: AVP-786 | Stage 1 AVP-786; Stage 2: AVP-786 |
|---|---|---|---|---|---|---|---|
| Stage 1 Baseline | 17.4 ± 2.44 | 17.3 ± 2.36 | — | — | — | — | — |
| Change from Baseline at Week 6 | -1.0 ± 2.10 | -1.0 ± 1.92 | — | — | — | — | — |
| Stage 2 Baseline | — | — | 16.5 ± 2.64 | 16.4 ± 2.84 | — | — | — |
| Change from Baseline at Week 12 | — | — | -0.5 ± 2.01 | -0.5 ± 1.93 | — | — | — |
Collected over All adverse events (AEs) were collected for approximately 90 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Placebo | 0/96 (0%) | 2/96 (2.1%) | 39/96 (40.6%) |
| All AVP-786 | 0/88 (0%) | 0/88 (0%) | 30/88 (34.1%) |
| Event | All Placebo | All AVP-786 |
|---|---|---|
| Urinary tract infectionInfections and infestations | 1/96 | 0/88 |
| SchizophreniaPsychiatric disorders | 1/96 | 0/88 |
| Event | All Placebo | All AVP-786 |
|---|---|---|
| HeadacheNervous system disorders | 5/96 | 2/88 |
| Dry mouthGastrointestinal disorders | 1/96 | 4/88 |
| NasopharyngitisInfections and infestations | 4/96 | 3/88 |
| DizzinessNervous system disorders | 3/96 | 3/88 |
| DiarrhoeaGastrointestinal disorders | 3/96 | 2/88 |
| SomnolenceNervous system disorders | 3/96 | 1/88 |
| Upper respiratory tract infectionInfections and infestations | 0/96 | 2/88 |
| Blood creatine phosphokinase increasedInvestigations | 0/96 | 2/88 |
| Vision blurredEye disorders | 0/96 | 2/88 |
| SedationNervous system disorders | 2/96 | 0/88 |
Baseline data are reported for members of the Safety Population, comprised of all participants who received at least one dose of study medication.
| Age, Continuous(Years) | Placebo | AVP-786 | Total |
|---|---|---|---|
| Mean | 44.9 ± 10.83 | 46.5 ± 12.04 | 45.4 ± 11.23 |
| Sex: Female, Male(Participants) | Placebo | AVP-786 | Total |
|---|---|---|---|
| Female | 27 | 18 | 45 |
| Male | 69 | 30 | 99 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | AVP-786 | Total |
|---|---|---|---|
| Hispanic or Latino | 12 | 4 | 16 |
| Not Hispanic or Latino | 84 | 44 | 128 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | AVP-786 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 4 | 4 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 53 | 25 | 78 |
| White | 36 | 18 | 54 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 1 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2015 to primary completion in Jul 2017, 22 months.
Results were first posted in Sep 2020, 3 years 1 month after primary completion. A results delay was requested in Jul 2018.
Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's 22 months is close to that.
Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Deudextromethorphan · Quinidine
Otsuka Pharmaceutical Development & Commercialization, Inc. →